Scientific Publications

Advancing dermatological science.

May 2025 Featured

JAMA Dermatology

Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body The ARRECTOR Phase 3 Randomized Clinical Trial

September 2024 Featured

JAMA Dermatology

Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials

March 2023 Featured

AAD 2023

Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial: Assessment of Pruritus

October 2024

Dermatology and Therapy

Patient and Healthcare Provider Perspectives on Disease Burden of Seborrheic Dermatitis in the United States: Results from a National Survey

October 2024

Journal of Drugs in Dermatology

Assessment of the Vehicle for Roflumilast Cream Compared to a Ceramide-Containing Moisturizing Cream in Mild Eczema

September 2024

Advances in Therapy

Patient and Healthcare Provider Perspectives on the Pathway to Diagnosis of Seborrheic Dermatitis in the United States

August 2024

JAAD

Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial

June 2024

Dermatology and Therapy

Patient Perspectives on the Prevalence and Burden of Intertriginous Psoriasis: Results from a National Survey of Adults with Psoriasis in the United States

May 2024

JAAD

Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial

March 2024

EADV 2024

Once-Daily Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Patients With Diverse Skin Types: Pooled Subgroup Analysis From the Phase 3 INTEGUMENT-1 and -2 Trials

March 2024

AAD 2024

Patient-Reported Outcomes With Roflumilast Foam 0.3% in Patients With Scalp and Body Psoriasis in the Phase 3 ARRECTOR trial

March 2024

AAD 2024

Roflumilast Cream 0.3% in Patients With Psoriasis: Improvement in Patient-Reported Outcomes and Pruritus From Two Pooled Phase 3 Trials (DERMIS-1/DERMIS-2)

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download